MaxCyte signed a strategic platform license (SPL) with Walking Fish Therapeutics which focuses on B cell-based therapeutics. Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments.
“We are delighted to partner with Walking Fish to help advance their B cell platform and support their innovative approach to develop novel therapies for the treatment of serious diseases,” said Doug Doerfler, president and CEO of MaxCyte.
Walking Fish is a privately held biotechnology company discovering and developing therapeutics that harness the power of B cells as protein factories and immune modulators. Walking Fish has created a technology platform addressing enzyme replacement therapies, cancer, autoimmune disease, and recombinant antibody production. Walking Fish’s first program, WFX-001, employs B cells as protein factories to generate a deficient enzyme in Fabry disease.
“Walking Fish draws its inspiration from the remarkable regenerative capacity of the Axolotl, colloquially known as a Walking Fish,” notes the company website.
